Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Bioinformation|December 6, 2013
DIACAN: Integrated Database for Antidiabetic and Anticancer Medicinal PlantsPriyanka James, Vipin Anithottam Mathai, Silpa Shajikumar, et al.
Blood Cancer Journal|January 20, 2023
Alternative splicing in multiple myeloma is associated with the non-homologous end joining pathwayEnze Liu, Nathan Becker, Parvathi Sudha, et al.
Iscience|September 1, 2021
YAP regulates alveolar epithelial cell differentiation and AGER via NFIB/KLF5/NKX2-1Jason J Gokey, John Snowball, Anusha Sridharan, et al.
Blood Cancer Journal|September 11, 2023
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myelomaEnze Liu, Parvathi Sudha, Nathan Becker, et al.
Genome Medicine|July 15, 2025
Utilizing genomics to identify novel immunotherapeutic targets in multiple myeloma high-risk subgroupsEnze Liu, Oumaima Jaouadi, Riya Sharma, et al.
Nature Communications|January 4, 2019
Single cell RNA analysis identifies cellular heterogeneity and adaptive responses of the lung at birthMinzhe Guo, Yina Du, Jason J Gokey, et al.
Research Square|August 30, 2023
Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myelomaTravis S Johnson, Parvathi Sudha, Enze Liu, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology|May 29, 2020
Glucocorticoid regulates mesenchymal cell differentiation required for perinatal lung morphogenesis and functionJames P Bridges, Parvathi Sudha, Dakota Lipps, et al.
Nature Communications|May 16, 2024
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myelomaTravis S Johnson, Parvathi Sudha, Enze Liu, et al.
Blood Advances|October 15, 2025
Diagnostic sequencing identifies high-risk markers and mechanisms of resistance to guide immunotherapy selectionParvathi Sudha, Phillip Pham, Wen Niu, et al.
Pageof 2